SCHEMBL4955161

SCHEMBL4955161

Cc1cc2cc(O)cc(O)c2c(=O)[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANTXR2 P58335 1/20 0.50
KDM4E B2RXH2 3/20 0.42
GAA P10253 2/20 0.42
PKM P14618 1/20 0.41
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 2/20 0.39
CYP3A4 P08684 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
CA9 Q16790 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NUAK1 O60285 2/20 0.38
IGF1R P08069 2/20 0.38
PIM1 P11309 2/20 0.38
SRC P12931 2/20 0.38
KDR P35968 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12060297 0.76 KDM4E (0.53) KDM4EGAAPKML3MBTL1ALDH1A1
SCHEMBL14243195 0.70 KDM4E (0.59) KDM4EGAAPKMALDH1A1HPGD
SCHEMBL29386163 0.70 ANTXR2 (0.50) ANTXR2GAAALPLALPIL3MBTL1
SCHEMBL704787 0.70 ANTXR2 (0.50) ANTXR2GAAALPLALPIL3MBTL1
SCHEMBL2588111 0.68 GAA (0.42) ANTXR2KDM4EGAAALPLALPI
SCHEMBL11976387 0.67 KDM4E (0.53) KDM4EGAAPKML3MBTL1ALDH1A1
SCHEMBL1520526 0.67 ANTXR2 (1.00) ANTXR2KDM4EGAAALPLALPI
SCHEMBL31636206 0.67 ANTXR2 (1.00) ANTXR2KDM4EGAAALPLALPI
SCHEMBL10181652 0.66 MAOA (0.47) KDM4EGAAPKMALPIL3MBTL1
SCHEMBL27157807 0.65 KDM4E (0.37) KDM4EGAAPKMMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4030948-A Polyimide containing silicones as protective coating on semiconductor device MICROSI, INC. 1977-06-21 US claimed
JP-2019365-A None JP disclosed
JP-2019365-A None JP disclosed
WO-2021079522-A1 METHOD, KIT, AND PROGRAM FOR DETERMINING CHARACTERISTIC OF TUMOR CELL GROUP 株式会社 東芝 2021-04-29 WO disclosed
US-7438950-B2 Metallic pattern forming method and conductive pattern material FUJIFILM CORPORATION (JP) 2008-10-21 US disclosed
US-20050266255-A1 Conductive film forming method and conductive material FUJI PHOTO FILM CO., LTD. 2005-12-01 US disclosed
US-20050266352-A1 Forming a region in which a graft polymer, that directly bonds to a surface of a base material that includes a polyimide is generated in a pattern shape; imparting electroless plating catalyst or a precursor thereof and electroless plating so as to form a metallic film in the pattern shape FUJI PHOTO FILM CO., LTD. 2005-12-01 US disclosed
US-6900239-B2 Tumor chemopotentiation using isocoumarin derivatives ILWZ ILEX PRODUCTS, INC. (US) 2005-05-31 US disclosed
US-20040024015-A1 Tumor radiosensitization and /or chemopotentiation using isocoumarin derivatives GLBC LLC 2004-02-05 US disclosed
EP-1363667-A1 TUMOR RADIOSENSITIZATION AND/OR CHEMOPOTENTIATION USING ISOCOUMARIN DERIVATIVES Ilex Oncology, Inc. (US) 2003-11-26 EP disclosed
US-6589981-B2 Combination treatment with ionizing radiation and/or chemotherapy ILEX ONCOLOGY, INC. 2003-07-08 US disclosed
US-20020165210-A1 Tumor chemopotentiation using isocoumarin derivatives GENZYME CORPORATION 2002-11-07 US disclosed
WO-2002072143-A1 TUMOR RADIOSENSITIZATION AND/OR CHEMOPOTENTIATION USING ISOCOUMARIN DERIVATIVES ILEX ONCOLOGY, INC (US) 2002-09-19 WO disclosed
US-20020019366-A1 Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives GLBC LLC 2002-02-14 US disclosed
JP-H0219365-A PRODUCTION OF INORGANIC ACID SALT OF DISULFIDE TYPE SIAMINE DERIVATIVE TAKEDA CHEM IND LTD 1990-01-23 JP disclosed
JP-H0219365-A PRODUCTION OF INORGANIC ACID SALT OF DISULFIDE TYPE SIAMINE DERIVATIVE TAKEDA CHEM IND LTD 1990-01-23 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019366-A1 Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives HCCS, IDH2, IDH3A ANTXR2 1599/4885KDM4E 3929/4885GAA 3618/4885
US-20020165210-A1 Tumor chemopotentiation using isocoumarin derivatives MCL1, IDH2, MYADM ANTXR2 805/4885KDM4E 3351/4885GAA 4136/4885
US-20040024015-A1 Tumor radiosensitization and /or chemopotentiation using isocoumarin derivatives HCCS, IDH2, IDH3A ANTXR2 1599/4885KDM4E 3929/4885GAA 3618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.